Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+ primary ductal breast carcinoma: A meta-analysis of microarray datasets

Autor: Alaa Alnefaie, Sarah Albogami, Yousif Asiri, Sahar M Alnefaie, Abdulaziz Abdullah Asiri
Rok vydání: 2021
Předmět:
0301 basic medicine
ER+ ductal carcinoma
ER
estrogen receptor
PI3K/Akt
phosphatidylinositol 3-kinase/protein kinase B
Pharmaceutical Science
FU
fluorouracil
OH●
hydroxyl radical
CASP3
0302 clinical medicine
skin and connective tissue diseases
TS
thymidylate synthase
TMX
tamoxifen
PM
personalized medicine
CMF
cyclophosphamide
methotrexate
and fluorouracil
Bcl2
B-cell lymphoma 2
Ductal Breast Carcinoma
Docetaxel
H2O2
hydrogen peroxide
030220 oncology & carcinogenesis
Original Article
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
medicine.drug
TGF-α/β
transforming growth factor alpha/beta
BC
breast cancer
RM1-950
IGF-1
insulin-like growth factor-1
ERBB2 (HER2)
FC
fold-change
NOX4
03 medical and health sciences
ROS
reactive oxygen species
Breast cancer
medicine
Chemotherapy
GSR
Doxorubicin
PI3K/AKT/mTOR pathway
CAF
cyclophosphamide
doxorubicin
and fluorouracil
Pharmacology
Bax
Bcl-2-associated X
business.industry
Cancer
PR
progesterone receptor
medicine.disease
DC
docetaxel and capecitabine
030104 developmental biology
Cancer research
HER2
human epidermal growth factor 2
Therapeutics. Pharmacology
business
Pharmacogenetics
Tamoxifen
Zdroj: Saudi Pharmaceutical Journal : SPJ
Saudi Pharmaceutical Journal, Vol 29, Iss 7, Pp 656-669 (2021)
ISSN: 1319-0164
Popis: Breast cancer arises as a result of multiple interactions between environmental and genetic factors. Conventionally, breast cancer is treated based on histopathological and clinical features. DNA technologies like the human genome microarray are now partially integrated into clinical practice and are used for developing new “personalized medicines” and “pharmacogenetics” for improving the efficiency and safety of cancer medications. We investigated the effects of four established therapies—for ER+ ductal breast cancer—on the differential gene expression. The therapies included single agent tamoxifen, two-agent docetaxel and capecitabine, or combined three-agents CAF (cyclophosphamide, doxorubicin, and fluorouracil) and CMF (cyclophosphamide, methotrexate, and fluorouracil). Genevestigator 8.1.0 was used to compare five datasets from patients with infiltrating ductal carcinoma, untreated or treated with selected drugs, to those from the healthy control. We identified 74 differentially expressed genes involved in three pathways, i.e., apoptosis (extrinsic and intrinsic), oxidative signaling, and PI3K/Akt signaling. The treatments affected the expression of apoptotic genes (TNFRSF10B [TRAIL], FAS, CASP3/6/7/8, PMAIP1 [NOXA], BNIP3L, BNIP3, BCL2A1, and BCL2), the oxidative stress-related genes (NOX4, XDH, MAOA, GSR, GPX3, and SOD3), and the PI3K/Akt pathway gene (ERBB2 [HER2]). Breast cancer treatments are complex with varying drug responses and efficacy among patients. This necessitates identifying novel biomarkers for predicting the drug response, using available data and new technologies. GSR, NOX4, CASP3, and ERBB2 are potential biomarkers for predicting the treatment response in primary ER+ ductal breast carcinoma.
Databáze: OpenAIRE
Externí odkaz: